Platelet-albumin (PAL) score as a predictor of perioperative outcomes and survival in patients with hepatocellular carcinoma undergoing liver resection in a Western center

Surg Oncol. 2022 Jun:42:101752. doi: 10.1016/j.suronc.2022.101752. Epub 2022 Mar 28.

Abstract

Background and objectives: Preoperative selection of patients with hepatocellular carcinoma (HCC) who will benefit from resection is highly advisable. The Platelet-Albumin (PAL) score was developed as a predictor of survival and morbidity following HCC resection. However, this has never been tested in western populations.

Methods: The impact of PAL score on perioperative outcomes and survival was evaluated and compared to Child-Pugh, Model for End-Stage Liver Disease (MELD), and albumin-bilirubin (ALBI) scores in patients who underwent HCC resection.

Results: A total of 182 patients were included. Postoperative morbidity was higher in patients with PAL grade II-III (P = 0.039), ALBI grade II-III (P = 0.028), and MELD >10 (P = 0.042). Post-hepatectomy liver failure (PHLF) occurred in 36 patients (19.8%) and was significantly higher in the PAL II-III and ALBI score II-III subgroup (P = 0.001). The PAL II-III group was the only one associated with higher perioperative mortality (OR 3.3, P = 0.036). The PAL score was an independent prognostic factor for overall survival in multivariate analysis (P = 0.018) and was the only one with the areas under the curve in ROC analysis significantly different for morbidity, PHLF, and mortality.

Conclusions: The PAL score predicts postoperative complications, mortality, PHLF, and survival following liver resection for HCC in western patients.

Keywords: Hepatectomy; Liver failure; Morbidity; Mortality; Survival.

MeSH terms

  • Bilirubin
  • Carcinoma, Hepatocellular* / pathology
  • End Stage Liver Disease* / surgery
  • Hepatectomy
  • Humans
  • Liver Neoplasms* / pathology
  • Prognosis
  • Retrospective Studies
  • Serum Albumin
  • Severity of Illness Index

Substances

  • Serum Albumin
  • Bilirubin